Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax TSLA Option Income Strategy ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $22.39 (market cap $706.06M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 181.5× YieldMax TSLA Option Income Strategy ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax TSLA Option Income Strategy ETF for 43 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TSLY | VRTX | |
|---|---|---|
Market Cap | $706.06M | $128.16B |
Volume | 229,346 | 806,603 |
Sector | Income / Options Overlay | Health |
52-Week High | $43.35 | $557.96 |
52-Week Low | $20.49 | $407.37 |
Typical Hold Time | 43 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $22.60, down 0.44% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.23, though recent analysis highlights concerns about capital erosion despite high yields. Technical indicators show support at $22 and resistance at $23, with neutral oscillators suggesting limited momentum.
While TSLY offers attractive income generation through its option income strategy, the fund faces structural limitations in capturing Tesla's upside potential. Recent downgrades to Hold reflect diminished return prospects amid Tesla's volatility changes. The primary risk remains the trade-off between high distributions and long-term capital preservation.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
